Targeting mutant p53: Evaluation of novel anti-p53R175H monoclonal antibodies as diagnostic tools

Abstract excerpt

Abstract About 50% of all cancers carry a mutation in p53 that impairs its tumor suppressor function. The p53 missense mutation p53 R175H (p53 R172H in mice) is a hotspot mutation in various cancer types. Therefore, monoclonal antibodies selectively targeting clinically relevant mutations like p53 R175H could prove immensely value. We aimed to evaluate the in vitro and in vivo binding properties of two novel...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Cancer-related Molecular Pathways
• Share to Cancer Research and Treatments
• Share to Virus-based gene therapy research